Claudin 3和表皮生长因子受体表达差异可预测三阴性乳腺癌中的BRCA1突变

Differential Claudin 3 and EGFR Expression Predicts BRCA1 Mutation in Triple-Negative Breast Cancer.

作者信息

Danzinger Sabine, Tan Yen Yen, Rudas Margaretha, Kastner Marie-Theres, Weingartshofer Sigrid, Muhr Daniela, Singer Christian F

机构信息

a Department of Obstetrics and Gynecology , Comprehensive Cancer Center, Medical University of Vienna , Vienna , Austria.

b Department of Pathology , Comprehensive Cancer Center, Medical University of Vienna , Vienna , Austria.

出版信息

Cancer Invest. 2018;36(7):378-388. doi: 10.1080/07357907.2018.1499934. Epub 2018 Aug 24.

DOI:10.1080/07357907.2018.1499934

PMID:30142017

Abstract

BRCA-1 mutation-associated triple-negative breast cancer (TNBC) has been hypothesized to exhibit a phenotype that is distinct from non-mutation carriers. We have analyzed immunohistochemically detected cytokeratins 5 and 14, epidermal growth factor receptor (EGFR), claudin (CLDN) 3, 4, and 7, and E-cadherin in 57 TNBC (32 BRCA1 and 8 BRCA2 tumors, 17 WT tumors). Positive staining of CLDN3 and negative EGFR expression in TNBC are associated with a BRCA1 mutation. EGFR and CLDN3 expression was able to predict the presence of BRCA1 mutation (area under curve 0.802, p < 0.001). This could help in guiding the decision for BRCA testing.

摘要

据推测，与BRCA-1突变相关的三阴性乳腺癌（TNBC）表现出与非突变携带者不同的表型。我们对57例TNBC（32例BRCA1肿瘤、8例BRCA2肿瘤、17例野生型肿瘤）进行了免疫组织化学检测，分析了细胞角蛋白5和14、表皮生长因子受体（EGFR）、claudin（CLDN）3、4和7以及E-钙黏蛋白。TNBC中CLDN3阳性染色和EGFR阴性表达与BRCA1突变相关。EGFR和CLDN3表达能够预测BRCA1突变的存在（曲线下面积为0.802，p<0.001）。这有助于指导BRCA检测的决策。